Frontiers in Digital Health
Development of a machine learning model to identify individuals with VCTE-derived at-risk MASH in a Spanish Mediterranean region
By Marta Cedenilla, David Marti-Aguado, Josep Redón and 7 others.
Abstract
Introduction While current guidelines recommend screening for liver disease in target populations, existing non-invasive tests have limitations in identifying at-risk metabolic dysfunction-associated steatohepatitis (MASH). Materials and methods This retrospective study used two large datasets from the general population in the Valencian Community region (Spain). The primary goal was to develop a machine learning model to identify individuals with at-risk MASH. The model was constructed using a well-characterized dataset ( n = 2,267) with available vibration-controlled transient elastography (VCTE). Supervised machine learning models (Random Forest and XGBoost) were trained using a 10-fold cross-validation to classify at-risk MASH individuals, defined as those with a controlled attenuation parameter (CAP) ≥ 275 dB/m together with a liver stiffness measurement (LSM) > 8 kPa and/or FibroScan-AST score (FAST) > 0.35. The final model, named VARM-7 (Valencia At-Risk MASH), comprised age and six commonly available laboratory variables. VARM-7 was sequentially applied to the Valencian public healthcare database ( n = 3,411,069) to estimate the proportion of at-risk MASH individuals in the overall population, and in target populations with type 2 diabetes mellitus (T2DM) and obesity. Results In the independent validation dataset, VARM-7 exhibited a significantly higher AUROC compared with Fibrosis-4 (FIB-4) for identifying at-risk MASH (0.84 vs . 0.64, respectively, p < 0.001). When sequentially applied to the overall Valencian Community population, 11.7% of individuals were estimated to have at-risk MASH, with increasing estimates up to 29.4% and 44.0% in subjects with obesity and T2DM, respectively. Conclusion VARM-7 showed strong performance in identifying individuals with a VCTE-derived at-risk MASH. Our model could improve disease screening and referral pathways, but external validation and prognostic evaluation are needed before its implementation.






